Welcome to our dedicated page for Inhibrx Biosciences news (Ticker: INBX), a resource for investors and traders seeking the latest updates and insights on Inhibrx Biosciences stock.
Inhibrx Biosciences, Inc. reports clinical and corporate updates for a pipeline of biologic therapeutic candidates developed with protein engineering platforms. The company’s programs include ozekibart (INBRX-109), a tetravalent death receptor 5 agonist antibody studied in oncology indications including chondrosarcoma, colorectal cancer and Ewing sarcoma, and INBRX-106, a hexavalent OX40 agonist evaluated in immuno-oncology settings such as head and neck squamous cell carcinoma.
Company developments commonly cover clinical trial data, regulatory submissions and designations, scientific conference presentations, quarterly and annual financial results, and capital resources. Inhibrx Biosciences also carries a completed corporate history tied to its 2024 separation from Inhibrx, Inc. following the sale of the INBRX-101 program.
Summary not available.
Summary not available.
Summary not available.
Inhibrx, Inc. (Nasdaq: INBX) announced the initiation of a registration-enabling trial for INBRX-101, a recombinant human AAT-Fc fusion protein targeting emphysema due to alpha-1 antitrypsin deficiency. This trial, named ElevAATe, includes 36 patients receiving doses every three weeks and aims to measure functional AAT concentration over 32 weeks across 35 sites in the U.S., Australia, and New Zealand. Additionally, the FDA lifted the partial clinical hold on INBRX-109, a DR5 agonist. Patient enrollment for INBRX-109 will resume next month, with data anticipated by late 2023 for Phase 1 cohorts and late 2024 for the registration trial data. The company continues to advance its clinical pipeline in oncology and rare diseases.
Inhibrx, Inc. (NASDAQ: INBX) reported its financial results for Q4 and fiscal year 2022, showing significant increases in cash and cash equivalents, totaling $273.9 million, up from $131.3 million in 2021. R&D expenses rose to $30.5 million in Q4, compared to $18.6 million in the previous year, and net loss widened to $40.9 million or $0.95 per share. Key clinical updates include the initiation of INBRX-101's trial for Alpha-1 Antitrypsin Deficiency expected in April 2023 and promising results from INBRX-105. Despite increased operational costs, the company remains focused on advancing its clinical pipeline.
Inhibrx, Inc. (NASDAQ: INBX) and NorthStar Medical Radioisotopes have announced a collaboration to develop innovative radiopharmaceuticals targeting cancer treatment. This partnership leverages Inhibrx's optimized single-domain antibodies for targeted alpha therapies and NorthStar’s capacity as a supplier of non-carrier added actinium-225 (Ac-225) and copper-67 (Cu-67). The collaboration aims to enhance the efficacy of targeted therapies while ensuring sufficient supply for clinical and commercial use.
Inhibrx, Inc. (Nasdaq: INBX) announced its participation in the 5th Annual HealthCONx Conference on November 30 at 8:45 a.m. PT. This virtual investor conference will include a live webcast of the presentation, available for at least 60 days on Inhibrx's investor website.
As a clinical-stage biopharmaceutical company, Inhibrx focuses on therapeutics for oncology and rare diseases, employing innovative protein engineering techniques. To learn more, visit www.inhibrx.com.
Inhibrx, Inc. (Nasdaq: INBX) reported updated efficacy and safety results from its Phase 1 trial of INBRX-109 for treating chondrosarcoma. Among 33 evaluable patients, the disease control rate was 87.9%, with 14 patients showing clinical benefits lasting over 6 months. The treatment exhibited a median progression-free survival of 7.6 months, with minimal adverse events. INBRX-109 has received Fast Track and orphan drug designations from FDA, highlighting its significance in treating this rare cancer.
On November 7, 2022, Inhibrx, Inc. (Nasdaq: INBX) reported its third quarter 2022 financial results, revealing a net loss of $35.3 million, or $0.90 per share, compared to a net loss of $20.6 million, or $0.54 per share in Q3 2021. Cash and equivalents stood at $146.1 million as of September 30, 2022, significantly up from $131.3 million at the end of 2021. The company highlighted progress in its clinical programs, including potential accelerated approval for INBRX-101 and orphan drug designation for INBRX-109.
Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company, announced its participation in several significant scientific conferences including the ACoP and SITC annual meetings. At ACoP (Oct 30-Nov 2, 2022), they will present a poster on INBRX-101 for Alpha-1 Antitrypsin Deficiency. The SITC (Nov 8-12, 2022) will showcase research on a targeted cytokine. Additionally, Inhibrx will present updates on INBRX-109 for chondrosarcoma at the CTOS meeting (Nov 16-19, 2022). Presentations will be accessible via their investor website.